

IN THE SPECIFICATION:

Please amend the specification as shown:

Please delete the paragraph on page 34, lines 5-8 and replace it with the following paragraph:

Fig. 6 shows the extent of prostate tumor growth inhibition by PRF1 specific RNA interference (Fig. 6C), and of total lymph node metastases upon using the same PRF1 specific RNA interference (Fig. 6D), with Fig. 6A (SEQ ID NO: 40) showing the basic vector design for the expression of siRNA and Fig. 6B the siRNA sequences used (SEQ ID NOS 14-16);

Please delete Table 1 and replace it with the following table:

Table 1: Overview of the various GeneBlocs used, their alias, mismatches relative to the target nucleic acid and the sequences' structural characteristics

GeneBloc No	Alias	MM	Sequence	SEQ ID NO.
70040	FLJ:1558L21	0	gct <u>caa</u> CTCTGCAGTacacga	4
70041	FLJ:1356L21	0	ct <u>uggt</u> CCCTTCAGAccagt <u>a</u>	5
70042	FLJ:1006L21	0	cagtt <u>uuu</u> TCCAACCACt <u>ggaa</u> t <u>u</u>	6
70043	FLJ:954L21	0	ccaaaAGTCAGTCgt <u>uct</u> <u>ctu</u>	7
70044	FLJ:975L21	0	gct <u>ucct</u> uGCCTCTAGTct <u>uccac</u>	8
70045	FLJ:470L21	0	gtugt <u>tuuc</u> ATCCTCAGGgt <u>ucat</u> uc	9
70046	FLJ:1412L21	0	gt <u>ucag</u> TAGTGATGCt <u>uccgat</u> u	10
70047	FLJ:571L21	0	ct <u>uuacc</u> AACTGGCTAggcat <u>uc</u>	11
70168	FLJ:954L21	4	ccgaaaAGAACAGTGct <u>uct</u> <u>ctu</u>	12

70169	FLJ:975L21	4	gct <u>cgt</u> CCCTGTAGTgt <u>ccac</u>	13
-------	------------	---	--	----

Please delete the paragraph on page 43, lines 1-2 and replace it with the following paragraph:

In addition it is to be noted that any of the „t“ above are actually „u“ given the fact that the above antisense oligonucleotides are GeneBlocs, i. e. third generation antisense oligonucleotides.

Please delete Table 2 and replace it with the following table:

Table 2: Overview of further GeneBlocs used

PTEN 48	guccuuuCCCAGCTT <u>acaguga</u> (<u>SEQ ID NO: 18</u>)
PTEN 52	cuggaucAGAGTCAGTggug <u>uca</u> (<u>SEQ ID NO: 19</u>)
PTEN 53	ucuccuuTTGTTCTG <u>cuaacga</u> (<u>SEQ ID NO: 20</u>)
PTEN 57	ugccacuGGTCTGTA <u>Auccagg</u> t (<u>SEQ ID NO: 21</u>)
mm PTEN 52	cuggaug <u>AGACTGAGTgc</u> ug <u>uca</u> (<u>SEQ ID NO: 22</u>)
mm PTEN 53	ucu <u>cauuTTCTTGTGcu</u> cacga (<u>SEQ ID NO: 23</u>)
p110□ 79	acuccaaAGCCTCTT <u>Gcucagu</u> u (<u>SEQ ID NO: 24</u>)
p110□ 82	uaccacaCTGCTGAAC <u>cagu</u> aa (<u>SEQ ID NO: 25</u>)
p110□ 88	caaauucCAGTGGTT <u>Cauuccaa</u> (<u>SEQ ID NO: 26</u>)
p110□ 93	ggcuaacTTCATCTT <u>Ccuucca</u> (<u>SEQ ID NO: 27</u>)
mm p110□ 79	acugcaa <u>ACCCTGTTGcu</u> acuu (<u>SEQ ID NO: 28</u>)
mm p110□ 93	ggcuaag <u>TTCITCATC</u> cuug <u>cca</u> (<u>SEQ ID NO: 29</u>)
PTEN 17	cccuuuCCAGCTT <u>Acaguga</u> (<u>SEQ ID NO: 30</u>)
mm PTEN 17	ccguuuGCACCTT <u>Agaguga</u> (<u>SEQ ID NO: 31</u>)

HIF1alpha 66	gguaguGGTGGCATTgcagu (<u>SEQ ID NO: 32</u>)
mm HIF1alpha 66	gguagaGGTGCCAATugcagu (<u>SEQ ID NO: 33</u>)
HIF1alpha 67	ugacucCTTTCCCTGcucugu (<u>SEQ ID NO: 34</u>)
mm HIF1alpha 67	ugacucCTTTCCCTGcucugu (<u>SEQ ID NO: 35</u>)
AKT1-GB	gcuuugATGTACTCCccucgu (<u>SEQ ID NO: 36</u>)
mm-AKT1	guguugATCTAGTCCccuccu (<u>SEQ ID NO: 37</u>)
AKT2-GB	uccuugTACCCAATGaaggag (<u>SEQ ID NO: 38</u>)
mm-AKT2	ucguugTAGCCAATCaacgag (<u>SEQ ID NO: 39</u>)